Valentin Aebischer

Dr. Valentin Aebischer

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2024 in Virchows Archiv
Verified
Journal Article
Open access
PDF file
SFStephan Forchhammer
Stephan Forchhammer
OPOltin Tiberiu Pop
Oltin Tiberiu Pop
MHMatthias Hahn
Matthias Hahn
VAValentin Aebischer
Valentin Aebischer
CSChristian M. Seitz
Christian M. Seitz
IBInes B. Brecht
Ines B. Brecht
Tumor-associated antigens (TAAs) are potential targets for T cell-based immunotherapy approaches in cutaneous melanoma. BNT111, an investigational lipoplex-formulated mRNA-based therapeutic cancer vaccine encoding melanoma TAAs NY-ESO-1, tyrosinase, MAGE-A3, and TPTE, is undergoing clinical testing in adults. Expression of these TAAs in pediatric melanoma is unclear but is a prerequisite for feasibility of this treatment approach in children with melanoma. Our main objective was to characterize expression of those TAAs in pediatric melanomas compared to control cohorts. In this retrospective case control study, protein and transcript expression of NY-ESO-1, tyrosinase, MAGE-A3, and TPTE were analyzed in a cohort of 25 pediatric melanomas, 31 melanomas of young adults, 29 adult melanomas, and 30 benign melanocytic nevi in children using immunohistochemical staining and digital pathology (QuPath) and reverse transcription quantitative PCR. Based on IHC analysis, pediatric melanomas expressed tyrosinase (100.0%), TPTE (44.0%), MAGE-A3 (12.0%), and NY-ESO-1 (8.0%). Young adult melanomas expressed tyrosinase (96.8%), NY-ESO-1 (19.4%), MAGE-A3 (19.4%), and TPTE (3.2%). Adult melanomas expressed tyrosinase (86.2%), MAGE-A3 (75.9%), NY-ESO-1 (48.3%), and TPTE (48.3%). Childhood melanocytic nevi only expressed tyrosinase (93.3%). Expression prevalence of individual TAAs did not differ between subtypes of pediatric melanoma, and no association with prognosis was found. All four TAAs were expressed in pediatric melanoma, albeit NY-ESO-1 and MAGE-A3 to a lesser extent than in adult melanoma. These data support the possibility of investigating vaccines targeting these TAAs for the treatment of pediatric melanoma.

20 July 2023 in Pigment Cell & Melanoma Research
Verified
Journal Article
Open access
VAValentin Aebischer
Valentin Aebischer
AAAmar Abu‐Ghazaleh
Amar Abu‐Ghazaleh
GMGisela Metzler
Gisela Metzler
LRLena Riedl
Lena Riedl
CGClaus Garbe
Claus Garbe
SFStephan Forchhammer
Stephan Forchhammer
The increasing number of melanoma patients makes it necessary to develop best possible strategies for prognosis assessment in order to recommend appropriate therapy and follow‐up. The prognostic significance of tumor cell pigmentation has not been fully elucidated. Hematoxylin and eosin (H&E)‐stained sections of 775 melanomas diagnosed between 2012 and 2015 were independently assessed for melanin pigment abundance by two investigators, and the impact on melanoma‐specific survival was calculated. Unpigmented melanomas (n = 99) had a melanoma‐specific survival of 67.7%, melanomas with moderate pigmentation (n = 384) had a melanoma‐specific survival of 85.9%, and strongly pigmented melanomas (n = 292) had a melanoma‐specific survival of 91.4% (p < .001). In an analysis of melanoma‐specific survival adjusted for pT stage and pigmentation, we found a nonsignificant impact of pigmentation abundance with a hazard ratio of 1.277 (p = .74). The study presented here provides evidence in a German cohort that patients with pigmented melanomas have a more favorable prognosis than those diagnosed with nonpigmented melanomas. Moreover, the abundance of pigmentation already seems to provide a first prognostic estimate. However, it does not appear to provide significant additional value for prognostic assessment according to the AJCC 2017 pT classification.

20 March 2024 in Pigment Cell & Melanoma Research
Verified
Journal Article
Open access
SFStephan Forchhammer
Stephan Forchhammer
VAValentin Aebischer
Valentin Aebischer
DLDaniela Lenders
Daniela Lenders
CSChristian M. Seitz
Christian M. Seitz
CSChristopher Schroeder
Christopher Schroeder
MHMatthias Hahn
Matthias Hahn
Pediatric melanomas are rare tumors that have clinical and histological differences from adult melanomas. In adult melanoma, the immunohistochemical marker PRAME is increasingly employed as a diagnostic adjunct. PRAME is also under investigation as a target structure for next‐generation immunotherapies including T‐cell engagers. Little is known about the characteristics of PRAME expression in pediatric melanoma. In this retrospective study, samples from 25 pediatric melanomas were compared with control groups of melanomas in young adults (18–30 years; n = 32), adult melanoma (>30 years, n = 30), and benign melanocytic nevi in children (0–18 years; n = 30) with regard to the immunohistochemical expression of PRAME (diffuse PRAME expression >75%/absolute expression). Pediatric melanomas show lower diffuse PRAME expression (4%) and lower absolute PRAME expression (25%) compared to young adult melanomas (15.6%/46.8%) and adult melanomas (50%/70%). A significant age‐dependent expression could be observed. An analysis of event‐free survival shows no prognostic role for PRAME in pediatric melanoma and young adult melanoma, but a significant association with diffuse PRAME expression in adulthood. The age dependency of PRAME expression poses a potential pitfall in the diagnostic application of melanocytic tumors in young patients and may limit therapeutic options within this age group. The immunohistochemical expression of the tumor‐associated antigen PRAME is an increasingly important diagnostic marker for melanocytic tumors and is gaining attention as a possible immunotherapeutic target in melanoma. As the available data primarily stem from adult melanoma, and given the clinical and histological distinctions in pediatric melanomas, our understanding of PRAME expression in this specific patient group remains limited. The age‐dependent low PRAME expression shown here constrains the use of this marker in pediatric melanoma and may also limit the use of immunotherapeutic strategies against PRAME in young patients.

22 March 2025 in EJC Skin Cancer
Verified
Journal Article
Open access
VAValentin Aebischer
Valentin Aebischer
LNLena Nanz
Lena Nanz
TATeresa Amaral
Teresa Amaral
CBCarola Berking
Carola Berking
TEThomas Eigentler
Thomas Eigentler
ULUlrike Leiter
Ulrike Leiter

4 April 2026 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Open access
PSPaul Schmidle
Paul Schmidle
TLTobias Lang
Tobias Lang
SSSebastian Springenberg
Sebastian Springenberg
DCDiego Calvopiña
Diego Calvopiña
TKTheresa Köhler
Theresa Köhler
SBStephan Alexander Braun
Stephan Alexander Braun
Summary: Background and Objectives: AI‐based image analysis is increasingly applied in pathology. Excluding fungal elements in PAS‐stained skin sections is labor‐intensive and well suited for AI assistance. While fungal detection in nails has been studied, skin‐biopsy applications and real‐world benefit remain limited. This study aimed to develop an AI algorithm for fungal detection in skin histology, create intuitive visualization software, and assess its diagnostic utility for pathologists. Patients and Methods: A total of 466 PAS‐stained cases from four institutions were digitised using three scanners. A lightweight UNet‐based model was trained with semi‐supervised learning and hard negative mining. Six dermatopathologists reviewed 204 independent cases in two phases: first without then with AI after a 4‐week washout. Inter‐observer agreement, diagnostic time, and AI‐human concordance were recorded; ROC analysis assessed algorithm performance. Results: The AI demonstrated strong correlation with human assessment (ROC‐AUC up to 0.949). At least one pathologist agreed with AI in 91.2% of cases. AI assistance increased Fleiss’ kappa from 0.67 to 0.82, raised full agreement from 64% to 78%, and halved diagnostic time, especially in negative cases. Software‐usability scored 9.5/10 and integration willingness 8.3/10. Conclusions: AI assistance improved accuracy, reduced reading time, and offered user‐friendly visualization, supporting integration into diagnostic workflows.

7 November 2024 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Open access
VAValentin Aebischer
Valentin Aebischer
MHMatthias Hahn
Matthias Hahn
DLDaniela Lenders
Daniela Lenders
GMGisela Metzler
Gisela Metzler
MSMartin Schaller
Martin Schaller
SFStephan Forchhammer
Stephan Forchhammer
Zusammenfassung: Hintergrund und Ziele: Haut‐ und Schleimhauterosionen mit histopathologischen Zeichen einer epidermalen Dysmaturation sind eine bekannte Nebenwirkung zytostatischer Chemotherapien, können aber auch unter niedrig dosierter Methotrexat (MTX)‐Therapie beobachtet werden. Ziel der Studie war die Charakterisierung der klinischen und histopathologischen Veränderungen.Patienten und Methodik: In einer Datenbankabfrage des Archivs für Dermatopathologie wurden 22 Patienten identifiziert, die unter niedrig dosiertem MTX eine epidermale Dysmaturation entwickelt hatten. Klinische, laborchemische sowie histopathologische Parameter wurden analysiert und statistisch mit SPSS ausgewertet.Ergebnisse: Die Patienten waren im Durchschnitt 69,1 Jahre alt und überwiegend weiblich. Die Hauptindikationen waren Psoriasis vulgaris und rheumatoide Arthritis. Klinisch zeigten sich erosive Plaques an der Injektionsstelle, an der Schleimhaut oder disseminierte Läsionen am gesamten Integument. Die Laborwerte der Patienten waren in der Regel unauffällig. Die Epidermis zeigte vergrößerte Keratinozyten mit blassem Zytoplasma und vergrößerten Zellkernen mit prominenten Nukleolen sowie eine Degeneration der Basalzellschicht. Die Dermis wies eine Infiltration mit neutrophilen Granulozyten, Lymphozyten und Histiozyten auf.Schlussfolgerungen: Mit dieser Studie möchten wir diagnostische Kriterien für die Methotrexat‐assoziierte epidermale Dysmaturation vorschlagen und das Bewusstsein unter Klinikern und Pathologen für diese Nebenwirkung schärfen, da eine frühzeitige Diagnose eine potenziell lebensbedrohliche Progression verhindern kann.